María Natalia Gandur Quiroga: Genetic testing in prostate cancer

María Natalia Gandur Quiroga shared a post by Advanced Prostate Cancer Consensus Conference, on X:

“Genetic testing in prostate cancer:

•  Increases risk in patients with inherited mutations
• Recommended for patients with advanced/metastatic disease
• Guides selection of targeted therapies and clinical trial options
• Critical to integrate genetic testing into primary care for precise screening and treatment.”

Quoting Advanced Prostate Cancer Consensus Conference‘s post:

“Genetic testing in prostate cancer management: Considerations informing primary care out on Cancer Journal for Clinicians

Inherited genetic mutations can greatly increase the risk of Prostate Cancer (PC) and are often linked to more aggressive forms of the disease, affecting both the patient and their family’s cancer risk Germline genetic testing is now highly recommended, especially for those with advanced or metastatic PC, as it can guide targeted therapies and clinical trial options. National guidelines advocate for testing across all stages of PC and for men at high risk due to family history.

Primary care providers play a crucial role in identifying at-risk individuals, emphasizing the need for their education on genetic testing’s role in PC management. This review underscores the importance of integrating genetic counseling, testing, and multidisciplinary care to improve outcomes.

Authors: Veda N. Giri, Todd M. Morgan, David S. Morris, Jacob E. Berchuck, Colette Hyatt MS, Mary-Ellen Taplin.”

Source: María Natalia Gandur Quiroga/X and Advanced Prostate Cancer Consensus Conference/X

Maria Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Ángel H. Roffo Oncology Institute in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors.  She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.